Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release Post author: Post published:April 20, 2026 Post category: Continue ReadingExpanded Access Program of AMTAGVI That is Out of Specification for Commercial Release
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation Post author: Post published:April 20, 2026 Post category: Continue ReadingA Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies Post author: Post published:April 20, 2026 Post category: Continue ReadingCD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel Post author: Post published:April 20, 2026 Post category: Continue ReadingExpanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma Post author: Post published:April 20, 2026 Post category: Continue ReadingA Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
The American Society of Hematology (ASH) Research Registry: A Multicenter Research Registry of Patients With Hematologic Disease Post author: Post published:April 20, 2026 Post category: Continue ReadingThe American Society of Hematology (ASH) Research Registry: A Multicenter Research Registry of Patients With Hematologic Disease
Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia Post author: Post published:April 20, 2026 Post category: Continue ReadingStudy of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma Post author: Post published:April 20, 2026 Post category: Continue ReadingA Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma Post author: Post published:April 20, 2026 Post category: Continue ReadingExpanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma
Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells Post author: Post published:April 20, 2026 Post category: Continue ReadingFecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells
